The symptoms of perimenopause extend well beyond hot flushes. Many women experience them for years before connecting them to hormonal change.
The reason perimenopause goes unrecognised for so long is not that women fail to notice the symptoms. It is that the symptoms rarely arrive as a set. Disrupted sleep, joint pain, low mood, palpitations, and difficulty finding words present as five separate problems, each plausibly attributable to work, stress, or age — and each likely to be investigated separately by a clinician who is not looking at them together.
What perimenopause actually is
The terminology matters here because it is routinely muddled. Menopause is a single point in time: the date twelve months after a final period. Perimenopause is the transition leading up to it, beginning when cycles first become noticeably variable and ending at that twelve-month mark.
Formal staging criteria published in 2012 define the transition by changes in cycle length and, later, by skipped periods. In practice it lasts around four years on average, though a substantial minority of women experience eight years or longer. With the average age of menopause around 51, that places the onset for many women in their mid-forties — and for some, their late thirties.
The hormonal picture is fluctuation, not decline
The mental model most people hold — oestrogen gradually tapering off — is wrong, and correcting it explains a great deal.
During perimenopause, follicle-stimulating hormone rises as the ovaries become less responsive, but oestradiol does not decline smoothly. It fluctuates erratically, often with peaks higher than anything seen in a normal premenopausal cycle, followed by sharp drops. The instability itself, rather than any particular level, appears to drive much of the symptom burden.
This accounts for the pattern women describe and clinicians sometimes doubt: symptoms that appear for a fortnight and vanish, cycles that are short then long, weeks of feeling entirely normal interspersed with weeks of feeling unrecognisable. It is also why the symptoms of perimenopause are frequently more disruptive than those of postmenopause, when levels are lower but stable.
Perimenopause is not a gradual decline in oestrogen. It is an erratic one — which is exactly why the symptoms are so inconsistent.
— WellnessLife editorial
The symptoms that do not get connected
- Cycle changes — usually the earliest sign: shorter cycles, heavier bleeding, then skipped periods
- Sleep disruption — insomnia and fragmented sleep occur independently of night sweats, not only because of them
- Mood changes — low mood, anxiety, irritability, and a specific quality of anger many women report as unfamiliar
- Cognitive symptoms — word-finding difficulty and reduced processing speed, measurable in cohort studies rather than merely reported
- Joint and muscle pain — common, under-recognised, and often attributed to ageing or exercise; frozen shoulder is associated with this period
- Genitourinary symptoms — vaginal dryness, discomfort during sex, urinary urgency, recurrent urinary infections
- Others frequently reported — palpitations, worsening migraines, dry eyes, tinnitus, skin changes, hair thinning, and altered fat distribution
Three of those deserve expanding, because they are the ones most often misattributed.
Mood. The risk of a depressive episode is elevated during the menopausal transition — cohort studies have found it two to four times higher than in the premenopausal years, with the greatest risk in women who have experienced depression before. This is a genuine increase in risk, not a reframing of ordinary stress, and it is the symptom most likely to result in a prescription for an antidepressant without perimenopause being considered at all.
Cognition. Longitudinal data has found measurable declines in verbal memory and processing speed during perimenopause specifically — which means “brain fog” is describing something real. The reassuring part is less well publicised: performance in these studies tended to recover after the transition. It appears largely transient rather than the beginning of a permanent decline, which is the fear most women bring to it.
Genitourinary symptoms are the exception to the general pattern. Most perimenopausal symptoms eventually settle. Vaginal and urinary symptoms tend to be progressive if untreated, and they respond well to treatment — which makes them the ones least worth waiting out.
Why blood tests usually cannot tell you
Women frequently request hormone testing and are then told the results are normal. Both the request and the confusion are understandable, and the explanation follows directly from the fluctuation described above: a hormone level measured on one day may be entirely unrepresentative of the next.
UK clinical guidance reflects this. For women over 45 with typical symptoms, diagnosis is made on the symptom picture rather than on FSH testing, because the test adds little and may actively mislead. Testing has a role in younger women, where premature ovarian insufficiency is a consideration, and in certain other specific circumstances. Otherwise, a normal result does not rule perimenopause out — and knowing that in advance saves a good deal of frustration.
What the evidence supports for treatment
This is a discussion to have with a clinician rather than a decision to make from an article, but the broad shape of the evidence is worth knowing.
Hormone therapy is the most effective treatment for vasomotor and genitourinary symptoms, with evidence also supporting benefit for sleep and, in some studies, mood. The risk picture has been substantially reappraised since the early 2000s: for most healthy women starting within roughly ten years of menopause or before 60, absolute risks are small, and transdermal oestrogen carries a different risk profile from oral. It is not appropriate for everyone, and personal and family history matter.
Vaginal oestrogen is worth naming separately. It acts locally with minimal systemic absorption, treats genitourinary symptoms effectively, and is generally considered suitable for many women who cannot or prefer not to take systemic hormone therapy.
Non-hormonal options have real support. Cognitive behavioural therapy is recommended in guidance for both vasomotor symptoms and mood. Certain antidepressants and gabapentin have evidence for hot flushes, and a newer class of non-hormonal drugs targeting the brain pathway involved in flushing has become available in some countries.
Resistance training earns a mention because bone and muscle loss accelerate in this period, and no medication substitutes for loading.
The practical takeaway
If you are in your forties and dealing with several of the symptoms above, the single most useful thing you can do is present them together rather than separately. A list — what started when, whether anything tracks with your cycle, how long each episode lasts — turns five unrelated complaints into a recognisable pattern, and it is considerably harder to dismiss.
Two specifics are worth holding onto. A normal hormone test does not mean this is not happening. And the cognitive symptoms, which frighten women more than any of the others, appear in the research to be temporary.
Sources
- Harlow SD, Gass M, Hall JE, et al. “Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging.” Menopause, 2012.
- Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. “Risk for new onset of depression during the menopausal transition.” Archives of General Psychiatry, 2006.
- Greendale GA, Huang MH, Wight RG, et al. “Effects of the menopause transition and hormone use on cognitive performance in midlife women.” Neurology, 2009.
- National Institute for Health and Care Excellence. Menopause: diagnosis and management (NG23).
- Santoro N. “Perimenopause: from research to practice.” Journal of Women’s Health, 2016.
